scaffold
Deviceimplantation of scaffold (eg Magmaris, Desolve, Others)
NCT Number: NCT03327961
The prospective study will investigate the clinical performance and long-term safety of scaffold implantation in a real world regional setting. The protocol includes two different networks. The first network includes all cath-labs in the Emilia-Romagna region (SHERPA). The second includes the centers partecipating into the MAGIC retrospective study. Both networks joined into the prospective SHERPA-MAGIC project. Investigators from both networks agreed in indications and strategy implanatation described by the protocol. In each center, after IRB approval, the patients will be enrolled according to established criteria.
Interested in participating?
Request Info18 year and older
All sexes
Observational
AO San Giovanni di Dio, Agrigento, Italy
Coronary stents are the default devices for the treatment of coronary artery disease in percutaneous coronary intervention (PCI) according to existing guidelines. However, thrombosis and restenosis are still the main limitations of current permanent metallic stents. In contrast to Bare Metal Stents (BMSs), Drug Eluting Stents (DESs) have a reduced restenosis rate due to the presence of antiproliferative agents in the coating layer of the stent surface and reduced rate of repeat revascularisation. However, late and very late stent thrombosis remains the limitation of DES in spite of prolonged dual antiplatelet therapy. Bioabsorbable scaffolds have been introduced to overcome limitations of permanent metallic stents.
The aim of this observational prospective study is to investigate the clinical performance and long-term safety of scaffold in a real world regional setting.
The investigators agreed in the following preferential/optimal indications:
The investigators agreed in the following strategy implantation:
The study organization is based on:
DATA SAFETY MONITORING BOARD (DSMB) All adverse events will be reported to the DSMB and reviewed on an on-going basis throughout the subject enrolment and follow-up period to ensure the safety of subjects enrolled in this study. The DSMB may request additional information as needed.
CORE LABORATORY ANALYSIS All coronary artery angiographies and percutaneous coronary interventions will be reviewed by an indipendent core-lab. The core-lab will perform quantitative coronary analysis and assessment of the agreement between implantation technique in each case and established criteria
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
implantation of scaffold (eg Magmaris, Desolve, Others)
Time frame: 1 year
cumulative occurence of cardiovascular death, target vessel myocardial infarction and target vessel revascularization. Target is defined the vessel treated with scaffold
Contact information is provided by the study sponsor or research team.
University Hospital of Ferrara
Other
Scaffold Implantation in Emilia-Romagna Plus Multi Absorbable Gears Intra Coronary
Acronym: SHERPA-MAGIC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07720349
Arterial Occlusive Diseases, Arteriosclerosis
Arendal, Norway
View Trial DetailsNCT02038127
Arterial Occlusive Diseases, Arteriosclerosis
Chuncheon, Gangwon-do, South Korea
View Trial DetailsNCT07190690
Arterial Occlusive Diseases, Arteriosclerosis
Alicante, Spain
View Trial DetailsNCT05611307
ASCVD, Arterial Occlusive Diseases
Indianapolis, Indiana, United States
View Trial Details